


AMSTERDAM UMC RESTARTS MRI GUIDED PROCEDURES WITH IMRICOR'S NORTHSTAR 3D MAPPING SYSTEM

Highlights:

- Amsterdam UMC have resumed routine cases after a pause to upgrade MRI systems and to integrate NorthStar 3D mapping system
- Amsterdam UMC are constructing a dedicated iCMR lab to perform MRI guided ablations showing a deep commitment to this growing field
- An existing MRI lab is being used for ablation procedures in the meantime.
- Amsterdam UMC is pursuing the final approvals required to participate in Imricor's VISABL-VT trial with more hospitals joining the trial in the near future

5 April 2024 – Melbourne, Australia (**4 April 2024** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that physicians at the Amsterdam University Medical Centre (Amsterdam UMC) restarted routine atrial flutter procedures today using Imricor's NorthStar 3D mapping system.

The team at Amsterdam UMC, led by Dr Marco Götte, MD PhD, who is a pioneer in the field of iCMR, and Professor Cornelis Allaart, MD PhD, successfully performed two procedures today, marking the official reactivation of Amsterdam UMC following the pandemic.



iCMR ablation procedures resumed today at Amsterdam UMC

Speaking of the experience, Dr Götte commented "Today we successfully performed two atrial flutter ablations with the new NorthStar system. Amazing tool, great functionality. NorthStar was extremely helpful in one patient with difficult anatomy. What may have taken several hours in the x-ray lab took less than an hour to perform in the iCMR with NorthStar.

"Many years ago, I envisioned being able to perform complex ablations in the MRI, and at Amsterdam UMC, we truly believe in the value MRI adds to these procedures. We are now at a point where that dream is a reality, and Imricor's technology provides us with the tools that allow us to move the field forward. We are excited to be at the forefront of iCMR, and we are excited about what we are going to do in the very near future."



Prof Allaart added “The addition of NorthStar really enhances the user experience. We are excited to now be able to move forward faster than ever. Even in challenging anatomy like we saw today, we were able to use real-time MRI and NorthStar to efficiently achieve the desired results.”

Imricor’s Chair and CEO, Steve Wedan, noted: “We continue to focus on activating and reactivating sites in 2024, and it is great to have such a high profile team and institution back up and running again. This is going to be an exciting year for Imricor and the field of interventional MRI, and much of the ground-breaking work will be done at Amsterdam UMC.”

Amsterdam UMC is the best hospital in the Netherlands, according to Newsweek¹, and is a Centre of Excellence for Imricor, where physicians from around the world can come for iCMR education and training, including seeing live procedures as they are performed.

Current procedures at Amsterdam UMC are performed in an existing MRI lab that has been upgraded for interventions, while the new Amsterdam UMC Heart Centre, under construction, will feature a brand new dedicated cardiology-owned iCMR lab. The site is expected to participate in both of Imricor’s clinical trials this year: VISABL-AFL and VISABL-VT. NorthStar is being used in procedures as part of an investigator-initiated study, which will help support NorthStar’s CE mark approval process.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor’s Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional

¹ <https://www.newsweek.com/rankings/worlds-best-hospitals-2024/netherlands>



procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union and the Kingdom of Saudi Arabia (KSA) with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in Australia, the U.S., and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter (pending in KSA) and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE Healthcare help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.